Table 3.

Key points in future HB research.

NK-1R	NK-1R: A new HB tumor marker
	NK-1R: Therapeutic target in HB patients, independent of the clinical stage/tumor biology
	NK-1R: Involved in the viability of HB cells?
	The tr-NK-1R, but not the fl-NK-1R, is associated with cancer?
	The response of the NK-1R antagonists depends on the differential expression of the receptor (truncated/full)?
	tr-NK-1R: Responsible for a constitutive growth stimulus in the HB cells?
	Overexpression of the tr-NK-1R: Correlates with poorer prognosis and advance HB stages?
	tr-NK-1R: Not internalized in the HB cells? Involved in the malignant transformation of the HB cells?
SP	Level of SP in the serum of HB patients
	SP activates GSK-3β in the HB cells (Warburg effect)?
	SP is released from the HB cells to promote neovascularization?
	SP triggers the migration of HB cells?